VAN NUYS, Calif.--(BUSINESS WIRE)--The Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code for the IpsiHand™ Upper Extremity Rehabilitation System by Neurolutions, Inc. This significant decision marks the first time a brain-computer interface (BCI) controlled therapy has been recognized with the receipt of a HCPCS code, setting a new benchmark for thought-activated controlled devices..

加利福尼亚州范纽斯（商业新闻短讯）--医疗保险和医疗补助服务中心（CMS）为Neurolutions，Inc.的IpsiHand™上肢康复系统建立了一个新的医疗保健通用程序编码系统（HCPCS）II级代码。这一重大决定标志着脑机接口（BCI）首次出现通过接收HCPCS代码，控制疗法已被认可，为思想激活的控制装置设定了新的基准。。

E0738 will be used to describe “Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, including microprocessor, all components and accessories” to describe the IpsiHand Upper Extremity Rehabilitation System.

E0738将用于描述“上肢康复系统，提供积极帮助以促进肌肉再教育，包括微处理器、所有组件和附件”，以描述IpsiHand上肢康复系统。

The IpsiHand System is a breakthrough therapeutic device and the only FDA-cleared, commercially available solution that enables non-invasive, at-home rehabilitation for stroke survivors affected by chronic motor deficits. Utilizing BCI technology, the IpsiHand enables stroke survivors to engage in thought-actuated therapy, connecting movement to the intent to move signals within the brain, helping rebuild neuronal pathways..

IpsiHand系统是一种突破性的治疗设备，也是唯一获得FDA批准的商业解决方案，可为受慢性运动缺陷影响的中风幸存者提供非侵入性的家庭康复。IpsiHand利用BCI技术，使中风幸存者能够进行思维驱动治疗，将运动与大脑内移动信号的意图联系起来，帮助重建神经元通路。。

CMS’ decision also includes a final Medicare benefit category determination, classifying the IpsiHand as Durable Medical Equipment (DME). This classification highlights the IpsiHand’s durability and appropriateness for home use, further emphasizing its role in advancing patient care and recovery outcomes.

CMS的决定还包括最终的医疗保险福利类别确定，将IpsiHand归类为耐用医疗设备（DME）。这种分类突出了IpsiHand在家庭使用中的耐用性和适用性，进一步强调了它在促进患者护理和恢复结果方面的作用。

Neurolutions CEO, Leo Petrossian, expressed enthusiasm over the CMS decision, stating:.

Neurolutions首席执行官Leo Petrossian对CMS的决定表示了热情，并表示：。

“We thank CMS for their decision and commitment to improving outcomes for stroke survivors by establishing a new HCPCS code, and for their support throughout the entire application process. This important milestone is a testament to the innovative spirit at Neurolutions, and a significant shift toward enhancing access to advanced rehabilitation technologies for stroke survivors across the nation.”.

“我们感谢CMS的决定和承诺，通过建立新的HCPCS代码来改善中风幸存者的预后，并感谢他们在整个应用过程中的支持。这一重要里程碑证明了Neurolutions的创新精神，也是全国中风幸存者获得先进康复技术的重大转变n、 “。

This is a step forward to establishing coverage for upper extremity rehabilitation therapies, opening the door for advancements in therapeutic BCI to generate better outcomes for patients and potentially lower the cost of care. Neurolutions is proud to partner with CMS to advance the forefront of the rapidly-growing frontier of BCI enabled post-stroke neurorehabilitation..

这是朝着建立上肢康复治疗覆盖率迈出的一步，为治疗性脑机接口的进步打开了大门，为患者产生更好的结果，并可能降低护理成本。Neurolutions很荣幸与CMS合作，推动脑卒中后神经康复快速发展前沿的前沿。。

About Neurolutions, Inc.

关于Neurolutions，Inc。

Neurolutions is a medical technology company dedicated to transforming the lives of patients suffering from neurological conditions. Our mission is to develop innovative solutions that address the unmet needs of patients while advancing the field of neurorehabilitation through cutting-edge research and development..

Neurolutions是一家医疗技术公司，致力于改变患有神经疾病的患者的生活。我们的使命是开发创新解决方案，解决患者未满足的需求，同时通过尖端研究和开发推进神经康复领域。。

The IpsiHand System is a breakthrough therapeutic device that uses brain-computer interface technology to help chronic stroke patients with an impaired upper extremity regain movement. The IpsiHand device has been clinically validated and has received FDA clearance for use in the United States.

IpsiHand系统是一种突破性的治疗设备，它使用脑-计算机接口技术帮助上肢受损的慢性中风患者恢复运动。IpsiHand设备已通过临床验证，并已获得FDA批准在美国使用。

https://neurolutions.com

https://neurolutions.com